Antisense & RNAi Therapeutics Market by Technology, Application, Route of Administration

Description

List of Tables

[195 Pages Report] The Antisense & RNAi Therapeutics Market size was estimated at USD 4.51 billion in 2023 and expected to reach USD 4.93 billion in 2024, at a CAGR 9.34% to reach USD 8.43 billion by 2030.

Global Antisense & RNAi Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 4.51 billion
Estimated Year [2024]	USD 4.93 billion
Forecast Year [2030]	USD 8.43 billion
CAGR (%)	9.34%

Antisense & RNAi Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antisense & RNAi Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antisense & RNAi Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Axolabs GmbH, Benitec Biopharma Limited, BioNTech SE, Carisma Therapeutics Inc., Dicerna Pharmaceuticals, Inc., Evox Therapeutics Ltd, Exicure, Inc., GenScript Biotech Corporation, InteRNA Technologies BV, Ionis Pharmaceuticals, Inc., miRagen Therapeutics, Inc., Regenxbio Inc., RXi Pharmaceuticals Corporation, Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Antisense RNA
- RNA Interference
  - miRNA
  - siRNA
Application
- Cardiovascular Diseases (CVDs)
- Genetic Disorders
- Infectious Diseases
- Neurodegenerative Disorders
- Oncology
- Renal Diseases
- Respiratory Disorders
Route of Administration
- Intra-dermal Injections
- Intraperitoneal Injections
- Intravenous Injections
- Pulmonary Delivery
- Topical Delivery
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antisense & RNAi Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antisense & RNAi Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antisense & RNAi Therapeutics Market?

4. What is the market share of the leading vendors in the Antisense & RNAi Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antisense & RNAi Therapeutics Market?

Product Code: MRR-8E22B61932D4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antisense & RNAi Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in geriatric populations and prevalence of chronic diseases worldwide
  - 5.1.1.2. Growing need for effective and novel therapeutics
  - 5.1.1.3. Increase in R&D activities on antisense and RNAi-based therapies
- 5.1.2. Restraints
  - 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Clinical advancements in antisense-RNAi-therapeutics
  - 5.1.3.2. Significant investments in the discovery and development of antisense-RNAi-therapeutics
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Antisense & RNAi Therapeutics Market, by Technology

6.1. Introduction
6.2. Antisense RNA
6.3. RNA Interference
- 6.4.1. miRNA
- 6.4.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Application

7.1. Introduction
7.2. Cardiovascular Diseases (CVDs)
7.3. Genetic Disorders
7.4. Infectious Diseases
7.5. Neurodegenerative Disorders
7.6. Oncology
7.7. Renal Diseases
7.8. Respiratory Disorders

8. Antisense & RNAi Therapeutics Market, by Route of Administration

8.1. Introduction
8.2. Intra-dermal Injections
8.3. Intraperitoneal Injections
8.4. Intravenous Injections
8.5. Pulmonary Delivery
8.6. Topical Delivery

9. Americas Antisense & RNAi Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antisense & RNAi Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Alnylam Pharmaceuticals, Inc.
- 13.1.2. Amarna Therapeutics BV
- 13.1.3. Arbutus Biopharma Corporation
- 13.1.4. Arrowhead Pharmaceuticals, Inc.
- 13.1.5. AstraZeneca plc
- 13.1.6. Axolabs GmbH
- 13.1.7. Benitec Biopharma Limited
- 13.1.8. BioNTech SE
- 13.1.9. Carisma Therapeutics Inc.
- 13.1.10. Dicerna Pharmaceuticals, Inc.
- 13.1.11. Evox Therapeutics Ltd
- 13.1.12. Exicure, Inc.
- 13.1.13. GenScript Biotech Corporation
- 13.1.14. InteRNA Technologies BV
- 13.1.15. Ionis Pharmaceuticals, Inc.
- 13.1.16. miRagen Therapeutics, Inc.
- 13.1.17. Regenxbio Inc.
- 13.1.18. RXi Pharmaceuticals Corporation
- 13.1.19. Sanofi S.A.
- 13.1.20. Silence Therapeutics plc
- 13.1.21. Sirnaomics, Inc.
- 13.1.22. Wave Life Sciences Ltd
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing